Interim Analysis of an Open-Label, Multi-Center Study of Ecopipam, a Dopamine D1 Receptor Antagonist, for Tic Reduction in Adults with Tourette Syndrome (P02.058)

CONCLUSIONS: In this open-label study, oral ecopipam appeared to reduce tic severity without causing weight gain. To confirm treatment safety and efficacy, further double blind, placebo-controlled randomized trials in children and in adults with TS are warranted.Supported by: Psyadon Pharmaceuticals, Inc.Disclosure: Dr. Gilbert has received personal compensation in an editorial capacity for Pediatrics Review and Education Program. Dr. Gilbert has received research support from Psyadon Pharmaceuticals and Otsuka Pharmaceuticals. Dr. Budman has received research support from Psyadon Pharmaceuticals and Otsuka Pharmaceuticals. Dr. Singer has recieved personal compensation in an editorial capacity for The Neurologist. Dr. Singer has received research support from Psyadon Pharmaceutials. Dr. Kurlan has received research support from Psyadon Pharmaceuticals. Dr. Kwan has received personal compensation for activities with Kinex Pharmaceutical, Psyadon Pharmaceutical, and Demerx Pharmaceutical. Dr. Chipkin has received personal compensation for activities with Psyadon Pharmaceuticals Inc. Dr. Chipkin has received compensation for serving on the board of directors of Psyadon Pharmaceuticals. Dr. Chipkin holds stock and/or stock options in Psyadon Pharmaceuticals.
Source: Neurology - Category: Neurology Authors: Tags: P02 Restless Legs Syndrome, Tourette Syndrome, and Dystonia Source Type: research